Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. - Wikidata - wikimedia - TriplyDB

Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.

Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.

http://www.wikidata.org/entity/Q30539596

about

Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters Future of coagulation factor replacement therapy Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future Dangerous liaisons: how the immune system deals with factor VIII Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias Present and future challanges in the treatment of haemophilia: a clinician's perspective Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate®) in hemophilia A A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models.Using DTA and DTAARRAY variables and programming in WinNonlin ASCII models to streamline user-defined calculation and data analysis.Management of hemophilia in Korea: the past, present, and future.Highly sensitive ligand-binding assays in pre-clinical and clinical applications: immuno-PCR and other emerging techniques.A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects.A single chain variant of factor VIII Fc fusion protein retains normal in vivo efficacy but exhibits altered in vitro activity.Regulation of immune responses by the neonatal fc receptor and its therapeutic implications Design of the INHIBIT trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance.Profile of efraloctocog alfa and its potential in the treatment of hemophilia A.FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes.Allometry of factor VIII and informed scaling of next-generation therapeutic proteins.Pharmacokinetics of recombinant bifunctional fusion proteins.Molecular approaches for improved clotting factors for hemophilia.Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives.Translational medicine advances in von Willebrand disease.The hope and reality of long-acting hemophilia products.Advances in the treatment of inherited coagulation disorders.Investigational drugs for coagulation disorders.Blood Clotting Factor VIII: From Evolution to Therapy.Designing first-in-human dose of coagulation factors: application of pharmacokinetic allometric scaling.Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia.Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity.Factor VIII therapy for hemophilia A: current and future issues.Changing paradigm of prophylaxis with longer acting factor concentrates.Joint WFH-ISTH session: issues in clinical trial design.Turoctocog alfa for the treatment of hemophilia a.Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs.Individualizing prophylaxis in hemophilia: a review.Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.Longer-acting clotting factor concentrates for hemophilia.Half-life extended factor VIII for the treatment of hemophilia A.

P2860

Q26801319-8F754A6A-F3B6-4251-9218-9BCA9D298E07 Q26820824-CCC9172D-04B5-42DD-85AD-888C071D7195 Q26822421-099CA17F-DE28-4176-B3DA-4BB5333D7483 Q26853631-20D349D8-975E-4283-AD75-BF3D967E3A5B Q27000818-1EAA7077-F11D-44C6-A8C6-6D8547565C6A Q27014771-7BB357C1-1864-4E60-A658-A26D09845B32 Q27026137-D22A3994-7167-41E5-B6C2-AFFD53B905FA Q28075081-E41FB492-A11A-4153-9970-5B2A59B4865B Q30426130-B6B78874-28FF-4B0D-BDB5-A9FF3717FB19 Q30884259-85F7854A-4925-4A9B-B53E-6BCE2E07EA56 Q34302456-94888155-DD5F-42F6-B50D-5B8632CD23B2 Q34486159-8E5BB0BD-64E2-4565-B892-8D24F1B90EC0 Q34503723-560AB1B9-EB51-4FBD-B970-78893A99D187 Q34557556-07019A3A-2F74-49DC-A7EC-AE6933B5B1E6 Q34818194-1DA462B2-2568-4AD2-8A32-D3FC53FB5C15 Q35168244-1D340526-6F01-4492-8BC2-81EF0284CE37 Q35565320-9F162EFB-B1DA-4BAE-B9A4-500067543E50 Q35612397-E69762D6-8EB6-4CFF-A082-36EDDE834263 Q36912731-FD87BAF4-74B3-4998-A0B8-02179E59DEF4 Q37033032-AA60C3A1-0C5B-49D4-AB52-F0FBD8D00C3B Q37334700-6727B876-C3DF-48FB-A7D5-694E66C1DB23 Q37489013-23F36AB2-1232-49BF-9024-670DB2E27B4A Q37494846-81576B0D-8675-41ED-9EE6-94CDB09606C9 Q37602563-D0655C50-0CDE-42E6-BB97-21AAD7EC2CB1 Q37990479-66619D5D-ED50-4AC1-8A1A-129F49366B70 Q38100271-F887E256-A1CF-4552-9ECA-22A00928D997 Q38106245-6A614473-19F7-43C0-989F-F629569B22E8 Q38118763-7BED0F10-7C2C-422D-A2C5-C83AA4833270 Q38121644-06C783B5-3367-4C06-82CE-B3879D75796F Q38127745-BBBD7E74-E20E-4CA5-A1E0-AFDB92F95F07 Q38188654-740799D7-B4D7-4B27-BC1B-D22423B21F2B Q38203350-441CFD35-E77A-4933-9ABD-6C8D72A30D48 Q38206858-778F5AD1-ABCC-4023-89A5-DBCFA60DA4B6 Q38206863-E4E8639C-0E1B-4F5F-AC45-3B6AD2FCFD00 Q38232780-FE2ABC02-3D2E-4497-A174-D0DC105227B6 Q38266890-54A8718A-A4DB-45FC-B892-CA7566AD2769 Q38323857-F59F541E-5EE2-457C-9B60-9FDFCE61A9B1 Q38371071-C59FA30E-1DB7-4804-9F08-E77416C73371 Q38543283-9E89B9F6-CFF2-405D-9103-147C8391B229 Q38543286-5C4DACAA-75C8-4AAC-8042-C81D8F259916

P2860

Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.

http://www.wikidata.org/entity/Q30539596

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Safety and prolonged activity ...... tein in hemophilia A patients.

@ast

Safety and prolonged activity ...... tein in hemophilia A patients.

@en

type

label

Safety and prolonged activity ...... tein in hemophilia A patients.

@ast

Safety and prolonged activity ...... tein in hemophilia A patients.

@en

prefLabel

Safety and prolonged activity ...... tein in hemophilia A patients.

@ast

Safety and prolonged activity ...... tein in hemophilia A patients.

@en

P1433

Q30539596-51DE85B0-FA16-4B48-902A-0399CCBDBDE9

P1476

Q30539596-6D9BEDA9-08A3-4AE2-B215-8257C3DDB58D

P2093

Q30539596-036D5E53-BA07-49C2-BD5F-84C80C72B437

Q30539596-03C15929-7E16-4F99-B207-5AAE6C94B58D

Q30539596-0A320747-379D-4CBE-AF06-1BAF6CA9B44F

Q30539596-1C07B223-7C09-4FAA-98F6-B12A25A1E875

Q30539596-256BB7E4-A77A-4CC3-B6C1-C7822D62A14F

Q30539596-3ABA3C77-1E46-422C-8636-057D14C9998A

Q30539596-44EF787D-DE41-486F-BC6D-5DDA2670671F

Q30539596-65EC46DB-87E0-43A0-B7BA-85C312EB10A1

Q30539596-67B30AEA-3D01-4270-8E4D-BD8C4627A7BD

Q30539596-68BFBB31-8FD1-46D0-A763-D0FCD3D4456A

P2860

Q30539596-08991298-6C42-42F2-8A41-A84ADFD9A82C

Q30539596-0914C288-08CB-49D0-8051-7DF0311CEE85

Q30539596-129331F0-52CA-434B-A90C-4375E8B03237

Q30539596-17891E79-C9CF-4152-9DED-70C4B4BA3B0B

Q30539596-17B1A7DC-E498-424D-9A83-811A2F1F924E

Q30539596-30087244-C476-4029-AE1C-45ED75DD32D9

Q30539596-3216D288-0878-4027-8654-B37179CAE9BC

Q30539596-38E7C922-B9C9-46DD-905B-434BA1977F60

Q30539596-52EF0F40-A682-4C32-90D1-20671BF332CD

Q30539596-5692A375-DDC4-41B0-9224-513B220B1230

P304

Q30539596-7A267CDC-C6B3-4202-BEB4-9B39ED8E0578

P31

Q30539596-E3AD1F7E-2D84-4544-8F55-66EF3A375687

P356

Q30539596-05A6CD13-397F-4FCC-8064-52DB4984A9DD

P407

Q30539596-4A2275A1-1F4D-400F-889A-A76CFA3FC1B0

P433

Q30539596-0B9000D5-F199-4898-A22C-81C8195F2748

P478

Q30539596-3DFAD88F-6AD4-4E4A-8BEF-234F81FBD690

P50

Q30539596-B146AA7A-CC3F-4E37-8782-1E5816143EF3

P577

Q30539596-7B14087D-8FB5-488F-92B1-540102776E37

P5875

Q30539596-D9CFE1BF-C168-4971-AA23-567981389A27

P698

Q30539596-1B892940-0C41-4946-9FF3-721D462CC2B8

P921

Q30539596-3FB4B6D0-6B66-40B1-ADEB-9357FCA80A10

Q30539596-706BC5CC-4146-4CB5-BC9C-B24FABB3995D

Q30539596-DACBB431-303C-4D8E-A7EC-8E0F4DA1747A

P932

Q30539596-74D6A7F1-1094-4C64-8046-6318151D1905

P356

BLOOD-2011-09-382846

P1433

P1476

Safety and prolonged activity ...... tein in hemophilia A patients.

@en

P2093

Alvin Luk

http://www.w3.org/2001/XMLSchema#string

Doris Quon

http://www.w3.org/2001/XMLSchema#string

Ella Li

http://www.w3.org/2001/XMLSchema#string

Glenn F Pierce

http://www.w3.org/2001/XMLSchema#string

Gregory Cheng

http://www.w3.org/2001/XMLSchema#string

Jaya Goyal

http://www.w3.org/2001/XMLSchema#string

Jennifer A Dumont

http://www.w3.org/2001/XMLSchema#string

Jerry S Powell

http://www.w3.org/2001/XMLSchema#string

Jurg Sommer

http://www.w3.org/2001/XMLSchema#string

Justin McCue

http://www.w3.org/2001/XMLSchema#string

P2860

Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment.

Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium

Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators.

The hemophilias--from royal genes to gene therapy.

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.

Assaying the circulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products.

A passionate kiss, then run: exocytosis and recycling of IgG by FcRn.

Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics.

Clearance mechanisms of von Willebrand factor and factor VIII.

FcRn: the neonatal Fc receptor comes of age.

P304

3031-3037

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-09-382846

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-01-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221728110

http://www.w3.org/2001/XMLSchema#string

P698

22223821

http://www.w3.org/2001/XMLSchema#string

P921

Coagulation factor VIII

P932

3646317

http://www.w3.org/2001/XMLSchema#string